Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Apatinib
Drug: Paclitaxel
Drug: Cisplatin
Procedure: Surgery

First Posted Date: 2019-06-11

Last Posted Date: 2024-04-30

Lead Sponsor: RenJi Hospital

Target Recruit Count: 196

Registration Number: NCT03982485

Locations: 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Phase 3

Active, not recruiting

Conditions: Carcinoma, Nonsquamous Non-small-cell Lung

Interventions: Biological: Pembrolizumab
Drug: Pemetrexed
Drug: Carboplatin
Drug: Cisplatin
Drug: Olaparib

First Posted Date: 2019-06-06

Last Posted Date: 2024-11-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 672

Registration Number: NCT03976323

Locations: 🇺🇸
Renovatio Clinical ( Site 0062), The Woodlands, Texas, United States
🇦🇺
Liverpool Hospital ( Site 1201), Liverpool, New South Wales, Australia
🇨🇦
Stronach Regional Cancer Centre ( Site 0101), Newmarket, Ontario, Canada

and more 175 locations

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Phase 3

Recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: Tislelizumab
Drug: Placebo
Drug: Cisplatin
Drug: Gemcitabine Hydrochloride
Drug: Carboplatin

First Posted Date: 2019-05-30

Last Posted Date: 2024-11-27

Lead Sponsor: BeiGene

Target Recruit Count: 420

Registration Number: NCT03967977

Locations: 🇨🇳
The Second Affiliated Hospital of Tianjin Medical University, Tianjin, Tianjin, China
🇨🇳
Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China

and more 14 locations

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Phase 1

Recruiting

Conditions: Metastatic Bone Sarcoma
Metastatic Unresectable Sarcoma
Resectable Sarcoma
Metastatic Malignant Neoplasm in the Lung
Metastatic Soft Tissue Sarcoma
Colorectal Cancer

Interventions: Drug: Cisplatin
Procedure: Isolated Chemotherapeutic Lung Perfusion
Procedure: Metastasectomy

First Posted Date: 2019-05-28

Last Posted Date: 2024-03-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 99

Registration Number: NCT03965234

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Phase 3

Active, not recruiting

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)

Interventions: Drug: Tislelizumab
Drug: Placebo
Drug: Paclitaxel
Drug: Cisplatin
Radiation: Radiotherapy

First Posted Date: 2019-05-21

Last Posted Date: 2024-11-28

Lead Sponsor: BeiGene

Target Recruit Count: 370

Registration Number: NCT03957590

Locations: 🇨🇳
The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Northern Jiangsu people's hospital, Yangzhou, Jiangsu, China

and more 30 locations

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Phase 2

Active, not recruiting

Conditions: Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Oropharyngeal Squamous Cell Carcinoma
Basaloid Squamous Cell Carcinoma
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Papillary Squamous Cell Carcinoma
Squamous Cell Carcinoma
Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Cisplatin
Procedure: Computed Tomography
Other: Fludeoxyglucose F-18
Radiation: Image Guided Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Biological: Nivolumab
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-05-16

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 384

Registration Number: NCT03952585

Locations: 🇺🇸
Ephrata Cancer Center, Ephrata, Pennsylvania, United States
🇺🇸
UPMC Uniontown Hospital Radiation Oncology, Uniontown, Pennsylvania, United States
🇺🇸
Summa Health System - Akron Campus, Akron, Ohio, United States

and more 491 locations

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Phase 3

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Biological: Pembrolizumab 200 mg
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Dietary Supplement: Folic acid 350-1000 μg
Drug: Dexamethasone 4 mg
Dietary Supplement: Vitamin B12 1000 μg
Drug: Saline solution

First Posted Date: 2019-05-15

Last Posted Date: 2024-06-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 40

Registration Number: NCT03950674

Locations: 🇯🇵
National Hospital Organization Nagoya Medical Center ( Site 0324), Nagoya, Aichi, Japan
🇯🇵
The Cancer Institute Hospital of JFCR ( Site 0323), Tokyo, Japan
🇯🇵
Kurume University Hospital ( Site 0326), Kurume, Fukuoka, Japan

and more 7 locations

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Phase 2

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Durvalumab
Drug: Osimertinib
Drug: Necitumumab
Drug: Carboplatin
Drug: Alectinib
Drug: Selumetinib
Drug: Datopotamab deruxtecan
Drug: Savolitinib
Drug: Gefitinib
Drug: Selpercatinib
Drug: Pemetrexed
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2019-05-10

Last Posted Date: 2024-07-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 248

Registration Number: NCT03944772

Locations: 🇸🇪
Research Site, Stockholm, Sweden

De-Escalation Therapy for Human Papillomavirus Negative Disease

Phase 2

Recruiting

Conditions: Human Papilloma Virus
Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Head and Neck
HPV-Related Squamous Cell Carcinoma
HNSCC

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiation
Drug: Nivolumab
Drug: Hydroxyurea Pill
Drug: 5-fluorouracil
Drug: Filgrastim Injection
Drug: Cisplatin

First Posted Date: 2019-05-10

Last Posted Date: 2024-08-15

Lead Sponsor: University of Chicago

Target Recruit Count: 36

Registration Number: NCT03944915

Locations: 🇺🇸
University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Phase 2

Active, not recruiting

Conditions: Testicular Cancer
Seminoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2019-05-06

Last Posted Date: 2024-06-25

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 135

Registration Number: NCT03937843

Locations: 🇨🇭
Kantonsspital Graubünden, Chur, Switzerland
🇨🇭
Hopital de Sion, Sion, Switzerland
🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland

and more 16 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy